Zobrazeno 1 - 10
of 279
pro vyhledávání: '"B. B. Scott"'
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 32(1)
Odanacatib (ODN) was investigated as an osteoporosis treatment in 292 men. Compared with placebo, odanacatib improved bone mineral density and led to sustained bone resorption decreases while producing relatively little bone formation reduction that
Autor:
K, Saag, F, Cosman, T, De Villiers, B, Langdahl, B B, Scott, A E, Denker, A, Pong, A C, Santora
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 32(9)
This post hoc analysis of a randomized, double-blind study of postmenopausal women with osteoporosis found that there were early increases in bone turnover markers and decreases in bone mineral density after discontinuation of long-term alendronate.
Autor:
J. A. Boice, Joachim Sieper, Walter P. Maksymowych, Susan Huyck, A. Tzontcheva, Y. Berd, D. van der Heijde, Sean P. Curtis, H. H. Weng, G. Bergman, Maxime Dougados, B. B. Scott
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Axial spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease characterized by inflammation of the sacroiliac (SI) joints and spine 1, 2. Patients with axial SpA experience chronic back pain and spinal stiffness as well as a reduction in
Autor:
William D. Tap, John Sarantopoulos, B. B. Scott, John W. Loewy, Lori Berk, Carolyn D. Britten, E. Poplin, Victor M. Rivera, Frank G. Haluska, Anthony W. Tolcher, Eric H. Rubin, Monica M. Mita, Pierre F. Dodion, Alain C. Mita
Publikováno v:
Annals of Oncology. 24:1104-1111
Background Ridaforolimus is an inhibitor of mTOR with evidence of antitumor activity in an I.V. formulation. This multicenter, open-label, 3 + 3 design nonrandomized, dose-escalation, phase I/IIa trial was conducted to determine the safety, pharmacok
Autor:
B. B. Scott, N. R. Lewis
Publikováno v:
Alimentary Pharmacology and Therapeutics. 24:47-54
With the appreciation of the high prevalence of coeliac disease there is increasing use of serology in screening asymptomatic people and testing those with suggestive features.To compare the sensitivities and specificities of the endomysial antibody
Autor:
B. B. Scott, J. R. Bebb
Publikováno v:
Alimentary Pharmacology & Therapeutics. 20:151-159
Summary Background : Details of the efficacy of the various drugs used in Crohn's disease are not readily available. Methods : We have reviewed all placebo controlled trials of the commonly used drugs in Crohn's disease for both the induction and mai
Autor:
B. B. Scott, J. R. Bebb
Publikováno v:
Alimentary Pharmacology & Therapeutics. 20:143-149
Summary Background : Details of the efficacy of the drugs used in ulcerative colitis are not readily available. Methods : We have reviewed all placebo-controlled trials of the commonly used drugs for both induction and maintenance of remission to det
Autor:
B. B. Scott, R N Cunliffe
Publikováno v:
Alimentary Pharmacology & Therapeutics. 16:647-662
The side-effects suitable for monitoring in patients with inflammatory bowel disease being treated with the four main groups of drugs (5-aminosalicylic acid preparations, azathioprine and 6-mercaptopurine, methotrexate, and corticosteroids) are revie
Autor:
B. B. Scott, N R Lewis
Publikováno v:
Alimentary pharmacologytherapeutics. 31(1)
Summary Background Following the appreciation of the importance of gliadin deamidation in the immunopathogenesis of coeliac disease, diagnostic tests based on antibodies to deamidated gliadin peptides have been developed and shown to have high sensit
Publikováno v:
Gut. 31:426-430
Cell counts and measurements of mucosal architecture were made on rectal biopsies from nine patients with total colitis, eight with left sided colitis, 15 with distal colitis, and 11 with proctitis. The mean total lamina propria cell count in proctit